According to a new report published by Allied Market Research, titled, Ulcerative Colitis Market by Disease Type, Route of Administration, and Molecule Type: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global ulcerative colitis market was valued at $4,785 million in 2016, and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. The mild ulcerative colitis disease type accounted for nearly half of the market share in 2016.
Advancements in ulcerative colitis treatment modalities has led to the emergence of biologics such as tumor necrosis factors (TNF) in developing drugs. This has led to the shift from traditional therapies towards engineered drugs that has also enhanced the efficacy rate of drugs
Download PDF Sample Report : https://www.alliedmarketresearch.com/request-sample/3965
Key Market Segments
- By Route Of Administration
- Oral
- Injectables
- By Disease Type
- Mild Ulcerative Colitis
- Moderate Ulcerative Colitis
- Severe Ulcerative Colitis
- By Molecule Type
- SMALL MOLECULES
- BIOLOGICS
Key Findings of the Ulcerative Colitis Market:
- The severe disease type segment is anticipated to grow with a CAGR of 6.7% from 2017 to 2023.
- U.S. was the highest shareholder in the North American ulcerative colitis market in 2016, and is poised to retain its lead during the forecast period.
- Biologics registered the highest CAGR of 6.9%.
- India is expected to grow at a significant rate of 7.1%.
- The small molecules segment accounted for half of the share in 2016, registering a CAGR of 6.1%.
In 2016, Asia-Pacific and LAMEA collectively accounted for about two-sevenths share of the market and are expected to continue this trend in the future. This is due to high incidence of ulcerative colitis disease in China, India, and the other developing economies. Moreover, rise in investments towards development of healthcare infrastructure done by key players in the ulcerative colitis treatment field drives growth in the Asia-Pacific region.
The key players operating in the global ulcerative colitis market are Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca plc, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., and Abbott Laboratories. The other prominent players in the value chain include Avaxia Biologics Inc., BioLineRx Ltd., Celgene Corporation, Mitsubishi Tanabe Pharma Corporation, and Salix Pharmaceuticals, Inc.
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3965
Similar Reports:
General Anesthesia Drugs Market
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.